Pregnancy and neonatal outcomes in women with HIV-1 exposed to integrase inhibitors, protease inhibitors and non-nucleoside reverse transcriptase inhibitors: an observational study
Tóm tắt
Recommended regimens for pregnant women with HIV-1 are composed of two nucleoside reverse transcriptase inhibitors (NRTI) plus either a ritonavir-boosted protease inhibitor (PI) or an integrase strand transfer inhibitor (ISTI), with non-nucleoside reverse transcriptase inhibitors (NNRTI) representing an alternative drug class. The study’s purpose was to compare these three options in terms of pregnancy outcomes. Data from a national observational study of pregnant women with HIV-1 were used. The analysis included all pregnancies reported between 2008 and 2018, ending in live births and exposed within 32 weeks of gestation to three-drug regimens composed of a NRTI backbone plus a PI, a NNRTI or a ISTI, without class switching during pregnancy. Clinical and laboratory outcomes were evaluated in univariate and multivariable analyses. Overall, 794 exposed pregnancies were analyzed (PI 78.4%, NNRTI 15.4%, ISTI 6.2%). Almost all outcomes had similar rates in the three groups. Women who received PI in pregnancy were less likely to be virologically suppressed at third trimester. PI use was associated with higher bilirubin and triglyceride levels, and ISTI use with a lower rate of low birthweight. The differences in viral suppression at third trimester and in low birthweight were not maintained in multivariable analyses that were adjusted for confounders. We found no major differences in a wide range of outcomes relevant for pregnant women with HIV. Such results are reassuring, and this information may be helpful in a context of preconception counseling when therapeutic choices for pregnancy are discussed between women and care providers.
Tài liệu tham khảo
Panel on treatment of HIV-infected pregnant women and prevention of perinatal transmission. Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. https://aidsinfo.nih.gov/guidelines. Accessed June 27 2019.
British HIV association. BHIVA guidelines on the management of HIV in pregnancy and postpartum 2018 (2019 interim update). https://www.bhiva.org/pregnancy-guidelines. Accessed June 27 2019.
Linee Guida Italiane sull’utilizzo dei farmaci antiretrovirali e sulla gestione diagnostico-clinica delle persone con infezione da HIV-1. http://www.salute.gov.it/portale/news/p3_2_1_1_1.jsp?lingua=italiano&menu=notizie&p=dalministero&id=3283. Accessed June 27 2019.
Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015;61:1715–25.
Uthman OA, Nachega JB, Anderson J, et al. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV. 2017;4:e21–30.
Stringer EM, Kendall MA, Lockman S, et al. Pregnancy outcomes among HIV-infected women who conceived on antiretroviral therapy. PLoS One. 2018;13:e0199555. https://doi.org/10.1371/journal.pone.0199555.
Short CE, Douglas M, Smith JH, Taylor GP. Preterm delivery risk in women initiating antiretroviral therapy to prevent HIV mother-to-child transmission. HIV Med. 2014;15:233–8.
Floridia M, Mastroiacovo P, Tamburrini E, et al. Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001-2011. BJOG. 2013;120:1466–75. https://doi.org/10.1111/1471-0528.12285.
Kotz D, Fidler J, West R. Very low rate and light smokers: smoking patterns and cessation-related behaviour in England, 2006-11. Addiction. 2012;107:995–1002.
Ministero della Salute–Sistema Nazionale per le linee guida. Linee guida per la gravidanza fisologica. Aggiornamento 2011. Available at: http://www.epicentro.iss.it/itoss/LineeGuida.asp. Accessed Jan 10 2019.
Bertino E, Spada E, Occhi L, et al. Neonatal anthropometric charts: the Italian neonatal study compared with other European studies. J Pediatr Gastroenterol Nutr. 2010;51:353–61.
Scheuerle A, Tilson H. Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf. 2002;11:465–75.
Delpisheh A, Brabin L, Brabin BJ. Pregnancy, smoking and birth outcomes. Womens Health. 2006;2:389–403.
Doyle P. The outcome of multiple pregnancy. Hum Reprod. 1996;11:110–7.
Sebayang SK, Dibley MJ, Kelly PJ, Shankar AV, Shankar AH. Determinants of low birthweight, small-for-gestational-age and preterm birth in Lombok, Indonesia: analyses of the birthweight cohort of the SUMMIT trial. Trop Med Int Health. 2012;17:938–50. https://doi.org/10.1111/j.1365-3156.2012.03039.x.
Williams PL, Crain MJ, Yildirim C, et al. Congenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infants. JAMA Pediatr. 2015;169:48–55. https://doi.org/10.1001/jamapediatrics.2014.1889.
Bulterys M, Berry RJ, Watts DH. Preconception antiretroviral therapy and birth defects: what is needed? AIDS. 2014;28:2777–80. https://doi.org/10.1097/qad.0000000000000500.
Vannappagari V, Thorne C, for APR and EPPICC. Pregnancy and neonatal outcomes following prenatal exposure to dolutegravir. J Acquir Immune Defic Syndr. 2019;81:371–8. https://doi.org/10.1097/qai.0000000000002035.
Zash R, Holmes L, Diseko M, et al. Neural-tube defects and antiretroviral treatment regimens in Botswana. N Engl J Med. 2019. https://doi.org/10.1056/nejmoa1905230[Epub ahead of print].
Givens M, Dotters-Katz SK, Stringer E, Rahangdale L, Kuller JA. Minimizing the risk of perinatal human immunodeficiency virus transmission. Obstet Gynecol Surv. 2018;73:423–32. https://doi.org/10.1097/ogx.0000000000000581.
Peters H, Francis K, Sconza R, et al. UK mother-to-child HIV transmission rates continue to decline: 2012-2014. Clin Infect Dis. 2017;64:527–8. https://doi.org/10.1093/cid/ciw791.
Sheldon WR, Blum J, Vogel JP, et al. Postpartum haemorrhage management, risks, and maternal outcomes: findings from the World Health Organization Multicountry Survey on Maternal and Newborn Health. Brit J Obstet Gynaecol. 2014;121:5–13. https://doi.org/10.1111/1471-0528.12636.